Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 14, 2014; 20(14): 3986-4000
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3986
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3986
HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation
Bjarte Fosby, Sigrid Næss, Johannes R Hov, Kirsten M Boberg, Espen Melum, Tom H Karlsen, Norwegian PSC Research Center, Division of Cancer, Surgery and Transplantation, Oslo University Hospital, N-0424 Oslo, Norway
Bjarte Fosby, Sigrid Næss, Johannes R Hov, Aksel Foss, Espen Melum, Kirsten Muri Boberg, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway
Sigrid Næss, Johannes R Hov, Kirsten M Boberg, Espen Melum, Helge Scott, Tom H Karlsen, KG Jebsen Inflammation Research Centre, Research Institute of Internal Medicine, Oslo University Hospital, N-0424 Oslo, Norway
Johannes R Hov, Kirsten M Boberg, Aksel Foss, Pål-Dag Line, Department of Transplantation Medicine, Division of Cancer, Surgery and Transplantation, Oslo University Hospital, N-0424 Oslo, Norway
James Traherne, John Trowsdale, Division of Immunology, Department of Pathology, University of Cambridge and Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 1TN, United Kingdom
Andre Franke, Institute of Clinical Molecular Biology, Christian-Albrechts-University, 24118 Kiel, Germany
Helge Scott, Department of Pathology, Divisoin of Diagnostics and Intervention, Institute of Pathology, Oslo University Hospital, N-0027 Oslo, Norway
Author contributions: Fosby B, Scott H and Karlsen TH conceived and designed the study; Fosby B, Boberg KM, Foss A, Line PD and Karlsen TH recruited the study subjects; Fosby B, Næss S, Traherne J, Trowsdale J, Franke A, Scott H and Karlsen TH performed the genotyping and immunohistochemistry; Fosby B, Næss S, Hov JR, Traherne J, Trowsdale J, Melum E, Scott H and Karlsen TH analyzed the data; Fosby B wrote the manuscript; all authors have read and approved the final manuscript prior to publication.
Supported by Norwegian PSC Research Center; the Wellcome Trust and the MRC with additional support from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (to Traherne J and Trowsdale J)
Correspondence to: Tom H Karlsen, MD, PhD, Professor, Norwegian PSC Research Center, Division of Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, Pb 4950 Nydalen, N-0424 Oslo, Norway. t.h.karlsen@medisin.uio.no
Telephone: +47-230-72469 Fax: +47-230-73510
Received: January 30, 2014
Revised: February 11, 2014
Accepted: March 7, 2014
Published online: April 14, 2014
Processing time: 133 Days and 14.4 Hours
Revised: February 11, 2014
Accepted: March 7, 2014
Published online: April 14, 2014
Processing time: 133 Days and 14.4 Hours
Core Tip
Core tip: Patients undergoing liver transplantation on the basis of primary sclerosing cholangitis (PSC) have a higher frequency of acute cellular rejections than non-PSC patients. Recent studies have determined the genetic susceptibility to PSC, of which genetic variants in the human leukocyte antigen complex represent the strongest risk factors. In the present report we show that these variants also influence risk of acute cellular rejection after liver transplantation in PSC. Moreover, we show that the same variants also involve in risk of acute cellular rejection in non-PSC recipients.